Read by QxMD icon Read

American Journal of Clinical Oncology

Lillie O'steen, Robert J Amdur, Christopher G Morris, Kathryn E Hitchcock, William M Mendenhall
HYPOTHESIS: While treating patients with postoperative radiotherapy (RT) for squamous cell carcinoma of the oral tongue or floor of mouth, we hypothesized a low risk of tumor recurrence in the contralateral neck in the absence of contralateral neck RT when the primary tumor is >1 cm from the midline regardless of tumor thickness (TT) or depth of invasion (DOI)>4 mm. OBJECTIVE: The policy at our institution for many years has been to limit postoperative RT to the ipsilateral side when the primary tumor does not cross the midline, regardless of TT or DOI...
September 18, 2018: American Journal of Clinical Oncology
Vivek Verma, Waqar Haque, Dandan Zheng, Ferdinand Osayande, Chi Lin
OBJECTIVES: The CROSS trial established neoadjuvant chemoradiation followed by surgery (nCRT-S) as superior to surgery alone (S) for locally advanced esophageal cancer (EC). However, because patients above 75 years of age were excluded, this comparison cannot be extrapolated to older patients. This study of a large, contemporary national database evaluated practice patterns in elderly patients ineligible for CROSS, and analyzed overall survival (OS) between nCRT+S, S, and definitive CRT (dCRT)...
September 13, 2018: American Journal of Clinical Oncology
Amanda J W Gibson, Haocheng Li, Adrijana D'Silva, Roxana A Tudor, Anifat A Elegbede, Shannon Otsuka, Dafydd Gwyn Bebb, Winson Y Cheung
OBJECTIVES: To compare the clinical characteristics and outcomes between relapsed and de novo metastatic non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: We reviewed all NSCLC diagnoses between January 1999 and December 2013 in the institutional Glans-Look Lung Cancer Database, which contains demographic, clinical, pathologic, treatment, and outcome information. Patients with distant metastasis at diagnosis (American Joint Committee on Cancer [AJCC] eighth edition, stage IV), the "de novo" cohort, were compared with the "relapsed" cohort, consisting of patients diagnosed with early stage disease (stage I/II) undergoing curative intent treatment and subsequently experiencing metastatic relapse...
September 11, 2018: American Journal of Clinical Oncology
Maclean Cook, Kelsey Baker, Mary Redman, Kristina Lachance, Macklin H Nguyen, Upendra Parvathaneni, Shailender Bhatia, Paul Nghiem, Yolanda D Tseng
OBJECTIVES: Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer with higher incidence among whites, elderly, and immunosuppressed patients. Although immunosuppressed MCC patients are at higher risk of recurrence and MCC-related death, it is unknown whether immunosuppression type is associated with differential outcomes. MATERIALS AND METHODS: We retrospectively evaluated 89 nonmetastatic MCC patients with a diagnosis of chronic immunosuppression...
September 11, 2018: American Journal of Clinical Oncology
Michele Prisciandaro, Raffaele Ratta, Francesco Massari, Giuseppe Fornarini, Salvatore Caponnetto, Roberto Iacovelli, Ugo De Giorgi, Gaetano Facchini, Sarah Scagliarini, Roberto Sabbatini, Claudia Caserta, Giorgia Peverelli, Alessia Mennitto, Elena Verzoni, Giuseppe Procopio
OBJECTIVE: The activity of cabozantinib in nonclear cell histologies has not been evaluated. MATERIALS AND METHODS: Data were collected across 24 Italian hospitals. Patients were aged 18 years and older with advanced nonclear cell renal cell carcinoma (RCC), with an Eastern Cooperative Oncology Group Performance Status 0 to 2, who had relapsed after previous systemic treatments for metastatic disease. Cabozantinib was administered orally at 60 mg once a day in 28 days cycles...
September 10, 2018: American Journal of Clinical Oncology
Daniel J Wale, Benjamin L Viglianti, Milton D Gross, Alice Ferretti, Domenico Rubello, Ka Kit Wong
Painful osseous metastasis resulting from castration-resistant prostate carcinoma is a common clinical problem. Historically, nuclear medicine offered several palliative beta-emitting radiopharmaceuticals targeting the skeleton with the goal of decreasing pain. However, these have largely been replaced by the alpha-emitting agent radium (Ra). Ra received Food and Drug Administration approval in 2013 for the treatment of metastatic castration-resistant prostate cancer with symptomatic bone metastases without visceral metastases...
September 10, 2018: American Journal of Clinical Oncology
Umberto Cariboni, Rita De Sanctis, Marta Giaretta, Emanuele Voulaz, Emanuela Morenghi, Piergiuseppe Colombo, Pierluigi Novellis, Edoardo Bottoni, Valentina Errico, Alessandro Crepaldi, Andrea Marrari, Pierina Navarria, Anna M Ascolese, Alberto Testori, Marta Scorsetti, Vittorio Quagliuolo, Armando Santoro, Marco Alloisio
BACKGROUND: Metastatic sarcoma patients have a poor prognosis with 3-year survival rate of 25%. About 30% of them present isolated lung metastases. We aimed to analyze the clinical outcome of sarcoma patients undergoing pulmonary metastasectomy (PM) and prognostic factors associated with local control, disease-free, and overall survival (OS). PATIENTS AND METHODS: All sarcoma patients undergoing PM at Humanitas Cancer Center were retrospectively reviewed. Analyzed variables included clinicopathologic, surgical, and survival data...
July 25, 2018: American Journal of Clinical Oncology
Antonio Cubillo, Rafael Álvarez-Gallego, Manuel Muñoz, Gregory Pond, Sofía Perea, Gema Sánchez, María Martin, Jesús Rodríguez-Pascual, Elena Garralda, Estela Vega, Emilio de Vicente, Yolanda Quijano, César Muñoz, Lisardo Ugidos, Rodrigo A Toledo, Manuel Hidalgo
BACKGROUND: Previous studies have shown that metastatic colorectal carcinoma (mCRC) patients treated with bevacizumab, experience variation in the plasma levels of angiogenesis growth factors and related cytokines, called angiogenic switch (AS). The aim of the present study was to analyze the relationship between AS and the clinical response during standard chemotherapy-bevacizumab treatment. PATIENTS AND METHODS: Patients with Eastern Cooperative Oncology Group 0-1 mCRC were eligible...
July 2, 2018: American Journal of Clinical Oncology
Nicholas G Zaorsky, Eric J Lehrer, Elizabeth Handorf, Joshua E Meyer
OBJECTIVE: To determine whether increasing biologically effective dose (BED) with stereotactic body radiation therapy (SBRT) is associated with improved local control (LC) or toxicities in patients with locally advanced pancreatic cancer. METHODS: A PICOS/PRISMA/MOOSE selection protocol was used to identify 15 studies across 12 institutions in 5 countries where patients received definitive SBRT for nonmetastatic disease. Biologically equivalent doses were calculated with an α/β of 10 (ie, BED10) for LC and acute toxicity and 3 (ie, BED3) for late toxicity...
June 30, 2018: American Journal of Clinical Oncology
Christina Bandera, Don S Dizon
No abstract text is available yet for this article.
June 30, 2018: American Journal of Clinical Oncology
José P Leone, Bjarni Haraldsson, Sarah L Mott, Bradley D McDowell, Elizabeth A Chrischilles
OBJECTIVES: The main objective of this study was to analyze treatment patterns of elderly patients with breast cancer brain metastases (BCBM), evaluate characteristics associated with treatment selection, and to analyze trends in overall survival (OS) over time. MATERIALS AND METHODS: We included women with BCBM reported to the Surveillance, Epidemiology, and End Results Medicare Program from 1992 to 2012. Treatments were recorded from Medicare claims from the date of brain metastases diagnosis until 60 days after...
June 30, 2018: American Journal of Clinical Oncology
Eric P Xanthopoulos, Surbhi Grover, Priya M Puri, Michael N Corradetti, Samuel P Heilbroner, Nandita Mitra, Charles B Simone, Lilie L Lin
BACKGROUND: Adjuvant radiation therapy improves overall survival in patients with vulvar cancer with 2+ positive lymph nodes, but its benefit remains uncertain for 1 positive lymph node. METHODS: Using the Surveillance, Epidemiology, and End Results (SEER) database, we identified node-positive, American Joint Committee on Cancer version 6-staged women with squamous cell vulvar carcinoma treated with and without radiation following surgery. The Kaplan-Meier approach assessed overall and cause-specific survival...
September 2018: American Journal of Clinical Oncology
Hiroko Machida, Aida Moeini, Marcia A Ciccone, Sayedamin Mostofizadeh, Tsuyoshi Takiuchi, Laurie L Brunette, Lynda D Roman, Koji Matsuo
OBJECTIVE: To examine survival outcomes of women with recurrent cervical cancer who received salvage chemotherapy with modified dose-dense paclitaxel (MDDP) monotherapy (paclitaxel 80 mg/m, administered on day 1, 8, and 15 without day 22). MATERIALS AND METHODS: A retrospective study was conducted to evaluate cause-specific survival after the first recurrence (SAR) of women with recurrent cervical cancer diagnosed between 2006 and 2014. Pooled analyses were performed to examine SAR in women who received MDDP monotherapy (n=17) for any treatment line, compared with those who received salvage chemotherapy with paclitaxel-doublet (n=18) and nonpaclitaxel regimens (n=52)...
September 2018: American Journal of Clinical Oncology
Ann F Callahan, Michael White, Philip Ituarte, Singh Gagandeep, Yanghee Woo, Yuman Fong, Laleh Melstrom
INTRODUCTION: Gastric carcinoid is a rare entity with complex management options. This study aims to determine if surgical intervention in patients with local, regional, and metastatic gastric carcinoid is associated with prolonged survival. MATERIALS AND METHODS: The California Cancer Registry merged with the California Office of Statewide Health Planning and Development was queried for patients with a diagnosis of gastric carcinoid (2000 to 2011). Clinicopathologic characteristics, management, and outcomes were evaluated...
September 2018: American Journal of Clinical Oncology
Francine E M Voncken, Rosa T van der Kaaij, Karolina Sikorska, Erik van Werkhoven, Jolanda M van Dieren, Cecile Grootscholten, Petur Snaebjornsson, Johanna W van Sandick, Berthe M P Aleman
OBJECTIVES: The objective of this study is to compare long-term outcomes between younger and older (70 y and above) esophageal cancer patients treated with curative intent. MATERIALS AND METHODS: Overall survival (OS), disease-free survival (DFS), and locoregional recurrence-free interval were compared between older (70 y and above) and younger (below 70 y) esophageal cancer patients treated between 1998 and 2013. Treatment consisted of neoadjuvant chemoradiotherapy with surgery or definitive chemoradiotherapy: 36 to 50...
September 2018: American Journal of Clinical Oncology
Amy R Rao, Daniel A Jones, Charles M Mendenhall, Syed N Rizvi, Jessica Kirwan, Christopher G Morris, Andrew Johns, William J McAfee, William M Mendenhall
OBJECTIVES: The purpose of this study was to retrospectively review outcomes for patients treated with definitive radiotherapy for carcinoma of the supraglottic larynx at a community hospital and to compare our results with the literature. MATERIALS AND METHODS: Treatment records of 46 patients with localized carcinoma of the supraglottic larynx treated from January 1987 through January 2012 were reviewed. Overall, 18 (39%) presented with stage I or II disease, whereas 28 (61%) presented with stage III to IV...
September 2018: American Journal of Clinical Oncology
Bismarck Odei, Jean-Claude Rwigema, Frederick R Eilber, Fritz C Eilber, Michael Selch, Arun Singh, Bartosz Chmielowski, Scott D Nelson, Pin-Chieh Wang, Michael Steinberg, Mitchell Kamrava
OBJECTIVES: Myxofibrosarcoma (MFS) is reported to have a higher risk of local recurrence (LR) following definitive surgical excision relative to other soft tissue sarcomas. We reviewed our clinical experience treating MFS to investigate predictors of LR. MATERIALS AND METHODS: We retrospectively reviewed treatment outcomes for MFS patients treated at our institution between 1999 and 2015. A total of 52 patients were identified. Median age was 65 years (range, 21 to 86 y)...
September 2018: American Journal of Clinical Oncology
Jonas Paludo, Karen Fritchie, Candace L Haddox, Peter S Rose, Carola A S Arndt, Randolph S Marks, Evanthia Galanis, Scott H Okuno, Steven I Robinson
OBJECTIVES: Extraskeletal osteosarcoma (EO) is a malignant neoplasm that produces osteoid, bone, and chondroid material without direct attachment to bone or periosteum. Surgical resection is the mainstay of treatment; the role of chemotherapy is not well defined. Therefore, we evaluated the impact of chemotherapy in the survival of patients with EO. METHODS: All EO patients seen at Mayo Clinic between 1990 and 2014 were assessed. Forty-three patients were included after all archived pathology slides were reviewed to confirm the diagnosis of EO...
September 2018: American Journal of Clinical Oncology
Tony Y Eng, Tiffany W Chen, Abhilasha J Patel, Jill N Vincent, Chul S Ha
BACKGROUND: Urethral cancer is a rare malignancy, representing <1% of all malignancies. Optimal management, due to its rarity, presents as a treatment dilemma for physicians. There is a lack of consensus regarding treatment as large randomized trials cannot be performed; thus, optimal management decisions rely on study of retrospective cases. This is a review of our institutional experience with urethral cancer treated with various treatment modalities. METHODS: A retrospective chart review was performed on 31 patients treated for primary cancer of the urethra from 1958 to 2008...
September 2018: American Journal of Clinical Oncology
Narek Shaverdian, Amar U Kishan, Darlene Veruttipong, D Jeffrey Demanes, Patrick Kupelian, Susan McCloskey, Michael L Steinberg, Christopher R King
OBJECTIVE: To assess the impact of the primary source of information used by prostate cancer patients to select a radiation treatment on their overall treatment experience and on treatment regret. METHODS: Patients with low to favorable intermediate-risk prostate cancer treated with stereotactic body radiation therapy, intensity-modulated radiation therapy, or high-dose rate brachytherapy were surveyed. The questionnaire explored the decision-making experience, treatment experience, and treatment regret...
September 2018: American Journal of Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"